Galvokimig, a multispecific, antibody-based IL-13, IL-17A, and IL-17F inhibitor, modulates lesional transcriptome and circulating biomarkers in atopic dermatitis: findings from a 12-week Phase 2a trial

Important Information Related to Your Request:

Galvokimig is an investigational product in clinical development. The safety and efficacy have not been established and it is not approved by the Food and Drug Administration, or by any health authority worldwide. The material below is provided in response to your specific search for information on UCBCOMPASS®. It is not intended to draw any conclusion regarding the efficacy and safety of galvokimig for any indication, dosage, or other claim.